Unveiling the Molecular Mechanisms of Glioblastoma through an Integrated Network-Based Approach
Open Access
- 1 October 2024
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2237
Abstract
Background/Objectives: Despite current treatments extending the lifespan of Glioblastoma (GBM) patients, the average survival time is around 15–18 months, underscoring the fatality of GBM. This study aims to investigate the impact of sample heterogeneity on gene expression in GBM, identify key metabolic pathways and gene modules, and explore potential therapeutic targets. Methods: In this study, we analysed GBM transcriptome data derived from The Cancer Genome Atlas (TCGA) using genome-scale metabolic models (GEMs) and co-expression networks. We examine transcriptome data incorporating tumour purity scores (TPSs), allowing us to assess the impact of sample heterogeneity on gene expression profiles. We analysed the metabolic profile of GBM by generating condition-specific GEMs based on the TPS group. Results: Our findings revealed that over 90% of genes showing brain and glioma specificity in RNA expression demonstrate a high positive correlation, underscoring their expression is dominated by glioma cells. Conversely, negatively correlated genes are strongly associated with immune responses, indicating a complex interaction between glioma and immune pathways and non-tumorigenic cell dominance on gene expression. TPS-based metabolic profile analysis was supported by reporter metabolite analysis, highlighting several metabolic pathways, including arachidonic acid, kynurenine and NAD pathway. Through co-expression network analysis, we identified modules that significantly overlap with TPS-correlated genes. Notably, SOX11 and GSX1 are upregulated in High TPS, show a high correlation with TPS, and emerged as promising therapeutic targets. Additionally, NCAM1 exhibits a high centrality score within the co-expression module, which shows a positive correlation with TPS. Moreover, LILRB4, an immune-related gene expressed in the brain, showed a negative correlation and upregulated in Low TPS, highlighting the importance of modulating immune responses in the GBM mechanism. Conclusions: Our study uncovers sample heterogeneity’s impact on gene expression and the molecular mechanisms driving GBM, and it identifies potential therapeutic targets for developing effective treatments for GBM patients.Keywords
Funding Information
- Knut och Alice Wallenbergs Stiftelse (72254)
- Trustlife Therapeutics (72254)
This publication has 104 references indexed in Scilit:
- The human protein atlas—Integrated omics for single cell mapping of the human proteomeProtein Science, 2023
- Ubiquitous Neural Cell Adhesion Molecule (NCAM): Potential Mechanism and Valorisation in Cancer Pathophysiology, Drug Targeting and Molecular TransductionsMolecular Neurobiology, 2022
- Immunoglobulin-like receptors and the generation of innate immune memoryImmunogenetics, 2022
- Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling PathwayDigestive Diseases and Sciences, 2021
- Suppression of PTTG1 inhibits cell angiogenesis, migration and invasion in glioma cellsMedical Oncology, 2020
- ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in brain tumors of glioma mouse modelsGlia, 2020
- Heme Oxygenase-1 and Carbon Monoxide Regulate Growth and Progression in Glioblastoma CellsMolecular Neurobiology, 2020
- Survival regulation of leukemia stem cellsCellular and Molecular Life Sciences, 2015
- Molecular Heterogeneity of Glioblastoma and its Clinical RelevancePathology and Oncology Research, 2014
- Identification of anticancer drugs for hepatocellular carcinoma through personalized genome‐scale metabolic modelingMolecular Systems Biology, 2014